Welcome to our dedicated page for Phibro Animal SEC filings (Ticker: PAHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Phibro Animal Health Corporation (Nasdaq: PAHC) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into Phibro’s animal health, mineral nutrition, and performance products businesses, as well as its governance, capital structure, and risk disclosures.
Key documents for PAHC include annual reports on Form 10-K and quarterly reports on Form 10-Q, where Phibro presents audited and interim financial statements, segment information for Animal Health, Mineral Nutrition, and Performance Products, and management’s discussion of factors affecting net sales, gross profit, operating expenses, and tax rates. These reports also describe product categories such as medicated feed additives, nutritional specialty products, vaccines, mineral nutrition products, and performance products.
Current reports on Form 8-K are particularly useful for tracking material events. For Phibro, recent 8-K filings have covered quarterly and annual financial results, updates to financial guidance, dividend declarations on Class A and Class B common stock, and a planned leadership transition in which Jack C. Bendheim is expected to move to an Executive Chairman role and Daniel (Dani) Bendheim is expected to become Chief Executive Officer and President as of a specified effective date. Other 8-K items document stockholder meeting results, including votes on director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm.
Phibro’s definitive proxy statement (DEF 14A) provides extensive detail on corporate governance, Board structure, executive compensation philosophy and programs, related party transactions, and security ownership of certain beneficial owners and management. It also explains the voting rights of Class A and Class B common stock and the matters presented at the annual meeting.
On Stock Titan, AI-powered tools can help summarize lengthy filings such as 10-Ks, 10-Qs, 8-Ks, and proxy statements for PAHC, highlighting segment performance, notable risk or governance disclosures, and key decisions by the Board and stockholders. Users can also review filings related to dividends and other corporate actions, and, where available, monitor insider and beneficial ownership information reported in SEC forms. Real-time updates from EDGAR ensure that new Phibro filings appear promptly, while AI-generated overviews make it easier to understand the implications of complex regulatory documents.
Phibro Animal Health Corporation declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. The dividend is payable on December 17, 2025 to stockholders of record at the close of business on November 26, 2025.
The company announced the dividend via a press release filed as Exhibit 99.1.
Phibro Animal Health (PAHC) insider filing shows planned sales by President and CEO Jack Bendheim under a Rule 10b5-1 plan adopted on May 30, 2025. BFI Co., LLC sold 3,520 Class A shares on 10/28/2025 at a weighted average price of $41.5561, 3,520 on 10/29/2025 at $41.6554, and 3,520 on 10/30/2025 at $41.0745. After these transactions, 44,440 shares were beneficially owned indirectly through BFI, and 16,840 shares were held directly.
Phibro Animal Health (PAHC) insider filings show sales of Class A common stock tied to a pre‑set Rule 10b5‑1 plan by BFI Co., LLC, over which CEO and director Jack Bendheim exercises voting and dispositive power. Reported transactions occurred on 10/22/2025 (11,859 shares at a weighted average price of $40.2692), 10/23/2025 (3,520 shares at $40.1796), and 10/24/2025 (3,520 shares at $41.749).
Following these trades, 55,000 shares were beneficially owned indirectly via BFI, and 16,840 shares were held directly. The 10b5‑1 trading plan was adopted on May 30, 2025.
Phibro Animal Health (PAHC) insider activity: Reporting persons BFI Co., LLC and Jack Bendheim (Director, 10% Owner, President and CEO) reported sales and a conversion. Under a Rule 10b5‑1 plan, BFI sold 700 Class A shares on 10/17/2025 at a weighted average price of $40.0319 and 16,075 Class A shares on 10/20/2025 at a weighted average price of $40.3842.
On 10/21/2025, 50,000 shares of Class B Common Stock were converted into 50,000 shares of Class A on a one‑for‑one basis. Following these transactions, 73,899 Class A shares were indirectly beneficially owned, and 16,840 Class A shares were directly owned. After the conversion, 20,086,034 shares of Class B were indirectly beneficially owned.
Insider sales reported for PHIBRO ANIMAL HEALTH CORP (PAHC). On 09/30/2025 the filing shows dispositions of Class A common stock by BFI Co., LLC and Jack Bendheim. BFI reported a sale of 20,664 shares at a weighted average price of $40.38 (individual trade prices ranged $40.00–$40.635) and Jack Bendheim reported a sale of 16,840 shares.
The filing states the BFI sales were effected under a Rule 10b5-1 trading plan adopted May 30, 2025. After the reported transactions, BFI is shown as beneficially owning 40,674 shares, and Jack Bendheim directly holds the 16,840 shares he sold before the disposition shown on this Form 4. The filing is signed by an attorney-in-fact on behalf of both reporting persons.
Jack Bendheim and BFI Co., LLC filed a Form 4 reporting insider transactions in Phibro Animal Health Corporation (PAHC). On 09/18/2025 BFI sold 7,022 shares of Class A common stock at a weighted average price of $40.2637 under a Rule 10b5-1 trading plan adopted May 30, 2025. On 09/19/2025 the reporting parties acquired 30,000 Class A shares via conversion of 30,000 Class B shares at no cash cost. Following the reported transactions, certain Class A holdings are reported as 61,338 shares (indirect) and derivative-related Class A shares underlying converted Class B stock total 30,000. Jack Bendheim is identified as a director, President and CEO, and a >10% owner; BFI is a >10% owner.
Jack Bendheim and BFI Co., LLC filed a Form 4 reporting insider transactions in Phibro Animal Health Corporation (PAHC). On 09/18/2025 BFI sold 7,022 shares of Class A common stock at a weighted average price of $40.2637 under a Rule 10b5-1 trading plan adopted May 30, 2025. On 09/19/2025 the reporting parties acquired 30,000 Class A shares via conversion of 30,000 Class B shares at no cash cost. Following the reported transactions, certain Class A holdings are reported as 61,338 shares (indirect) and derivative-related Class A shares underlying converted Class B stock total 30,000. Jack Bendheim is identified as a director, President and CEO, and a >10% owner; BFI is a >10% owner.
Phibro Animal Health Corporation filed a definitive proxy describing items for its 2025 Annual Meeting, including the election of three Class III directors to serve until the 2028 annual meeting, an advisory vote to approve named executive officer compensation and a separate advisory vote on the frequency of such votes, and ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal 2026.
The filing discloses strong fiscal year results: net sales of $1,296.2 million (up 27%), net income of $48.3 million (increase of $45.8 million), diluted EPS of $1.19 (up $1.13), adjusted EBITDA of $183.7 million (up 65%), and adjusted net income of $84.9 million (up 76%, adjusted diluted EPS $2.09).
Compensation disclosures show the CEO’s annual total compensation of $5,284,122, median employee pay of $55,854, and a CEO-to-median pay ratio of 95:1. Multiple Bendheim family members serve as officers/directors; certain NEO pension and retirement arrangements are detailed.
Phibro Animal Health Corporation filed a definitive proxy describing items for its 2025 Annual Meeting, including the election of three Class III directors to serve until the 2028 annual meeting, an advisory vote to approve named executive officer compensation and a separate advisory vote on the frequency of such votes, and ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal 2026.
The filing discloses strong fiscal year results: net sales of $1,296.2 million (up 27%), net income of $48.3 million (increase of $45.8 million), diluted EPS of $1.19 (up $1.13), adjusted EBITDA of $183.7 million (up 65%), and adjusted net income of $84.9 million (up 76%, adjusted diluted EPS $2.09).
Compensation disclosures show the CEO’s annual total compensation of $5,284,122, median employee pay of $55,854, and a CEO-to-median pay ratio of 95:1. Multiple Bendheim family members serve as officers/directors; certain NEO pension and retirement arrangements are detailed.
Jack Bendheim and BFI Co., LLC reported insider sales of Phibro Animal Health Corporation (PAHC) Class A common stock executed under a Rule 10b5-1 trading plan adopted May 30, 2025. Between 09/09/2025 and 09/11/2025 the reporting persons sold a total of 16,840 shares in multiple transactions: 14,080 shares on 09/09/2025 at a weighted average price of $40.3296, 3,520 shares on 09/10/2025 at a weighted average price of $41.2885, and 3,520 shares on 09/11/2025 at a weighted average price of $40.948. The filings show beneficial ownership held indirectly by BFI with Bendheim exercising voting and dispositive power; Bendheim disclaims beneficial ownership except for his pecuniary interest. Forms were signed by an attorney-in-fact on 09/11/2025.
Form 144 notice for Phibro Animal Health Corporation (PAHC) indicating a proposed sale of 281,600 shares of Class A common stock through Goldman Sachs & Co. LLC on 09/04/2025. The filing lists an aggregate market value of $11,002,112 against 20,367,574 shares outstanding, and shows the securities were originally acquired on 04/14/2014 in a private placement from the issuer, with the consideration described as an exchange of securities. The filer reports no securities sold in the past three months and includes the standard representation that the selling person is not aware of undisclosed material adverse information.
Phibro Animal Health Corporation filed a Form 8-K stating that on August 27, 2025 it issued a press release with its operating results for the fourth quarter and fiscal year ended June 30, 2025, along with financial guidance for the fiscal year ending June 30, 2026. The press release is furnished as Exhibit 99.1. The company notes that this information is being furnished, not filed, under the Securities Exchange Act of 1934, so it is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.